The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative : Phenotypic Drug Discovery. / Quancard, Jean; Bach, Anders; Cox, Brian; Craft, Russell; Finsinger, Dirk; Guéret, Stéphanie M.; Hartung, Ingo V.; Laufer, Stefan; Messinger, Josef; Sbardella, Gianluca; Koolman, Hannes F.

In: ChemMedChem, Vol. 16, No. 11, 2021, p. 1737-1740.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Quancard, J, Bach, A, Cox, B, Craft, R, Finsinger, D, Guéret, SM, Hartung, IV, Laufer, S, Messinger, J, Sbardella, G & Koolman, HF 2021, 'The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery', ChemMedChem, vol. 16, no. 11, pp. 1737-1740. https://doi.org/10.1002/cmdc.202100041

APA

Quancard, J., Bach, A., Cox, B., Craft, R., Finsinger, D., Guéret, S. M., Hartung, I. V., Laufer, S., Messinger, J., Sbardella, G., & Koolman, H. F. (2021). The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery. ChemMedChem, 16(11), 1737-1740. https://doi.org/10.1002/cmdc.202100041

Vancouver

Quancard J, Bach A, Cox B, Craft R, Finsinger D, Guéret SM et al. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery. ChemMedChem. 2021;16(11):1737-1740. https://doi.org/10.1002/cmdc.202100041

Author

Quancard, Jean ; Bach, Anders ; Cox, Brian ; Craft, Russell ; Finsinger, Dirk ; Guéret, Stéphanie M. ; Hartung, Ingo V. ; Laufer, Stefan ; Messinger, Josef ; Sbardella, Gianluca ; Koolman, Hannes F. / The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative : Phenotypic Drug Discovery. In: ChemMedChem. 2021 ; Vol. 16, No. 11. pp. 1737-1740.

Bibtex

@article{37252494360a408a8701043f66d62e22,
title = "The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery",
abstract = "Phenotypic drug discovery has a long track record of delivering innovative drugs and has received renewed attention in the last few years. The promise of this approach, however, comes with several challenges that should be addressed to avoid wasting time and resources on drugs with undesired modes of action or, worse, false-positive hits. In this set of best practices, we go over the essential steps of phenotypic drug discovery and provide guidance on how to increase the chance of success in identifying validated and relevant chemical starting points for optimization: selecting the right assay, selecting the right compound screening library and developing appropriate hit validation assays. Then, we highlight the importance of initiating studies to determine the mode of action of the identified hits early and present the current state of the art.",
author = "Jean Quancard and Anders Bach and Brian Cox and Russell Craft and Dirk Finsinger and Gu{\'e}ret, {St{\'e}phanie M.} and Hartung, {Ingo V.} and Stefan Laufer and Josef Messinger and Gianluca Sbardella and Koolman, {Hannes F.}",
note = "This article also appears in: EuroMedChem Talents",
year = "2021",
doi = "10.1002/cmdc.202100041",
language = "English",
volume = "16",
pages = "1737--1740",
journal = "Farmaco",
issn = "1860-7179",
publisher = "Wiley - V C H Verlag GmbH & Co. KGaA",
number = "11",

}

RIS

TY - JOUR

T1 - The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative

T2 - Phenotypic Drug Discovery

AU - Quancard, Jean

AU - Bach, Anders

AU - Cox, Brian

AU - Craft, Russell

AU - Finsinger, Dirk

AU - Guéret, Stéphanie M.

AU - Hartung, Ingo V.

AU - Laufer, Stefan

AU - Messinger, Josef

AU - Sbardella, Gianluca

AU - Koolman, Hannes F.

N1 - This article also appears in: EuroMedChem Talents

PY - 2021

Y1 - 2021

N2 - Phenotypic drug discovery has a long track record of delivering innovative drugs and has received renewed attention in the last few years. The promise of this approach, however, comes with several challenges that should be addressed to avoid wasting time and resources on drugs with undesired modes of action or, worse, false-positive hits. In this set of best practices, we go over the essential steps of phenotypic drug discovery and provide guidance on how to increase the chance of success in identifying validated and relevant chemical starting points for optimization: selecting the right assay, selecting the right compound screening library and developing appropriate hit validation assays. Then, we highlight the importance of initiating studies to determine the mode of action of the identified hits early and present the current state of the art.

AB - Phenotypic drug discovery has a long track record of delivering innovative drugs and has received renewed attention in the last few years. The promise of this approach, however, comes with several challenges that should be addressed to avoid wasting time and resources on drugs with undesired modes of action or, worse, false-positive hits. In this set of best practices, we go over the essential steps of phenotypic drug discovery and provide guidance on how to increase the chance of success in identifying validated and relevant chemical starting points for optimization: selecting the right assay, selecting the right compound screening library and developing appropriate hit validation assays. Then, we highlight the importance of initiating studies to determine the mode of action of the identified hits early and present the current state of the art.

U2 - 10.1002/cmdc.202100041

DO - 10.1002/cmdc.202100041

M3 - Journal article

C2 - 33825353

VL - 16

SP - 1737

EP - 1740

JO - Farmaco

JF - Farmaco

SN - 1860-7179

IS - 11

ER -

ID: 272712245